Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease
ZYMFENTRA® is the first and only FDA-approved subcutaneous (SC) formulation of infliximab approved for the maintenance treatment of adult patients with moderately... Read more.
HE DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Hawaiian Electric Industries, Inc. Investors to Secure Counsel Before Important October 23 Deadline in Securities Class Action – HE
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hawaiian Electric Industries, Inc.... Read more.
Marqeta Study: Even Satisfied Credit Cardholders Are Shopping For Their Next Card, Seeking Tailored Rewards and Embedded Finance Experiences
36% of US consumers surveyed said they plan to apply for a new credit card in the next 12 months, with that number among 18-44 year olds booming to 55%. 74% of US... Read more.
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc.... Read more.
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
U.S. BLA Filing in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (CRC) Planned for Midyear 2024 Potential Accelerated Filings for Advanced Pancreatic... Read more.
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results... Read more.
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented... Read more.
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
KEYTRUDA plus enfortumab vedotin significantly prolonged overall survival (OS) by 53% – an improvement in median OS of more than 15 months – compared... Read more.
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab vedotin... Read more.
Unit21 Launches Real-Time Monitoring to Fight Real-Time Fraud
LAS VEGAS–(BUSINESS WIRE)–#Money2020–Unit21, a leading provider in risk and compliance solutions, today announced the launch of Real-Time Monitoring... Read more.